Clinical trial
A Randomized Phase II Open-Label Study of Two Different Dose Levels of PX-12 in Patients With Advanced Carcinoma of the Pancreas Whose Tumors Have Progressed on Gemcitabine or on a Gemcitabine-Containing Combination
NCT00417287 is registered in ClinicalTrials.gov with Cascadian Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Open-Label Study of Two Different Dose Levels of PX-12 in Patients With Advanced Carcinoma of the Pancreas Whose Tumors Have Progressed on Gemcitabine or on a Gemcitabine-Containing Combination
- Lead sponsor
- Cascadian Therapeutics Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2006
- Completion date
- April 30, 2009
- Enrollment
- 17 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.